Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

627 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M; Swiss HIV Cohort Study Group. Kaufmann GR, et al. Among authors: hirschel b. Arch Intern Med. 2003 Oct 13;163(18):2187-95. doi: 10.1001/archinte.163.18.2187. Arch Intern Med. 2003. PMID: 14557216
Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders.
Tarr PE, Taffé P, Bleiber G, Furrer H, Rotger M, Martinez R, Hirschel B, Battegay M, Weber R, Vernazza P, Bernasconi E, Darioli R, Rickenbach M, Ledergerber B, Telenti A; Swiss HIV Cohort Study. Tarr PE, et al. Among authors: hirschel b. J Infect Dis. 2005 May 1;191(9):1419-26. doi: 10.1086/429295. Epub 2005 Mar 22. J Infect Dis. 2005. PMID: 15809899 Free article.
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M; Swiss HIV Cohort Study. Kaufmann GR, et al. Among authors: hirschel b. Clin Infect Dis. 2005 Aug 1;41(3):361-72. doi: 10.1086/431484. Epub 2005 Jun 24. Clin Infect Dis. 2005. PMID: 16007534 Free article.
Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Rickenbach M, Ledergerber B, Günthard HF; Swiss HIV Cohort Study. von Wyl V, et al. Among authors: hirschel b. Clin Infect Dis. 2008 Apr 15;46(8):1299-309. doi: 10.1086/528863. Clin Infect Dis. 2008. PMID: 18444871 Free article.
Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland.
von Wyl V, Yerly S, Bürgisser P, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Francioli P, Bonhoeffer S, Ledergerber B, Günthard HF; Swiss HIV Cohort Study. von Wyl V, et al. Among authors: hirschel b. Clin Infect Dis. 2009 Apr 1;48(7):979-87. doi: 10.1086/597352. Clin Infect Dis. 2009. PMID: 19228107 Free article.
627 results